SG Americas Securities’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-38,541
| Closed | -$143K | – | 3733 |
|
|
2017
Q4 | $143K | Buy |
38,541
+25,464
| +195% | +$104K | ﹤0.01% | 2661 |
|
|
2017
Q3 | $53K | Buy |
+13,077
| New | +$50K | ﹤0.01% | 3314 |
|
|
2017
Q2 | – | Sell |
-11,456
| Closed | -$47K | – | 3718 |
|
|
2017
Q1 | $47K | Buy |
+11,456
| New | +$48.2K | ﹤0.01% | 3123 |
|
|
2015
Q4 | – | Sell |
-5,842
| Closed | -$96K | – | 3146 |
|
|
2015
Q3 | $96K | Buy |
5,842
+3,797
| +186% | +$77.8K | ﹤0.01% | 1893 |
|
|
2015
Q2 | $46K | Sell |
2,045
-7,148
| -78% | -$113K | ﹤0.01% | 2482 |
|
|
2015
Q1 | $90K | Sell |
9,193
-3,623
| -28% | -$35.5K | ﹤0.01% | 2299 |
|
|
2014
Q4 | $146K | Buy |
12,816
+8,616
| +205% | +$93.5K | ﹤0.01% | 2663 |
|
|
2014
Q3 | $48K | Sell |
4,200
-12,053
| -74% | -$184K | ﹤0.01% | 2493 |
|
|
2014
Q2 | $316K | Buy |
+16,253
| New | +$287K | ﹤0.01% | 1850 |
|
|
2013
Q3 | – | Sell |
-9,389
| Closed | -$88K | – | 3071 |
|
|
2013
Q2 | $88K | Buy |
+9,389
| New | +$121K | ﹤0.01% | 2117 |
|
SG Americas Securities's CASC Position: Q1 2018 in Review
SG Americas Securities sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 38,541 shares — an estimated $143K sold.
SG Americas Securities first reported a position in CASC in Q2 2013 and held it in 10 quarters. The position peaked at $316K in Q2 2014. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- SG Americas Securities reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- SG Americas Securities sold 38,541 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $143K.
- SG Americas Securities first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 10 quarters.
- SG Americas Securities's Cascadian Therapeutics, Inc. position peaked at $316K in Q2 2014.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on SG Americas Securities's 13F filing for Q1 2018, filed 3 May 2018.